The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Open accessPublished version of a preprint
Abstract
Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq). Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) was explored. Results: Between December 2015 and May 2019, 195 patients (95%) had enough tissue for RNA-seq; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% versus 33%, respectively (P = 0.02). In patients with basal-like tumors treated with modified FOLFIRINOX (n = 22), the progression rate was 60% compared with 15% in classical PDAC (P = 0.0002). Median OS in the intention-to-treat population (n = 195) was 9.3 months for classical versus 5.9 months for basal-like PDAC (HR, 0.47; 95% confidence interval, 0.32–0.69; P = 0.0001). GATA6 expression by RNA-seq highly correlated with the classifier (P < 0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariate analysis, GATA6 expression was prognostic (P = 0.02). In exploratory analyses, basal-like tumors, could be identified by keratin 5, were more hypoxic and enriched for a T-cell–inflamed gene expression signature. Conclusions: The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression. See related commentary by Collisson, p. 4715
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
The control of the false discovery rate in multiple testing under dependency
Benjamini, Y., & Yekutieli, D. (2001) · The Annals of Statistics · doi:10.1214/aos/1013699998 · Cited by 10,490
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Cited by
Sorted by citations
Items 301–353 of 353
Dynamics of the microbiome in pancreatic cancer from inception to invasion
Pfisterer, N. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10152
Gao, Z., Kang, S. W., Erstad, D. J., Azar, J. H., Buren, G. V., Fisher, W. P., Sun, Z., Rubinstein, M. P., Lee, H., & Camp, E. R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1274783
Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker?
Rivière, D., Aarntzen, E. H. J. G., van Geenen, E., Chang, D. K.-F., de Geus‐Oei, L., Brosens, L. A. A., van Laarhoven, C. J. H. M., Gotthardt, M., & Hermans, J. J. (2023) · HPB · doi:10.1016/j.hpb.2023.11.010
Faut-il réséquer les métastases hépatiques d’adénocarcinome du pancréas ?
Muzzolini, M., Lupinacci, R. M., Bachet, J., Lassoued, D., Sauvanet, A., & Gaujoux, S. (2024) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2023.09.007
Söderqvist, S., Viljamaa, A., Geyer, N., Strell, C., Hekmati, N., Engstrand, J., Sparrelid, E., Salmén, C., Heuchel, R. L., Zacharouli, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.584614
Spatial Transcriptomics of IPMN Reveals Divergent Indolent and Malignant LineagesPreprint
Iyer, M. K., Fletcher, A. A., Shi, C., Chen, F., Kanu, E. N., Eckhoff, A. M., Bao, M., Frankel, T. L., Chinnaiyan, A. M., Nussbaum, D. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620810
Yıldızhan, S. E., Demir, İ. E., Sever, E. A., Zeybek, D. K., Sezerman, O. U., & Ceyhan, G. O. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632859
P., G. F. P. D. M., Lins, M. P., da Fontoura, J. C., Osvaldt, A. B., Machado, S. M. D. S., Filippi‐Chiela, E. C., & Bonorino, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.08.637283
Rademaker, G., Hernandez, G. A., Dahal, S., Miller‐Phillips, L., Li, A., Luan, C., Qui, L., Liegeois, M. A., Wang, B., Wen, K. W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.22.649912
Biomarker-directed therapy for pancreatic cancer
Pishvaian, M. J., & Brody, J. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-800684-9.00001-0
Hypoxia-induced metastatic heterogeneity in pancreatic cancer
Gunasekaran, P. M., Wang, Q., Guseva, P., Chang, Y., Chauhan, R., Kley, A., Xu, M., Lee, G., Marshall, G., Roy, S. G., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76143-w
Therapeutic pancreatic cancer biomarkers and pharmacogenetics
Langer, A., Souček, P., Vymetalkova, V., Rizzato, C., Bunduc, Ș., Nikas, I. P., Hlaváč, V., Kroupa, M., Farinella, R., Campa, D., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.002
Zhang, Y.-F., Gan, W., Wang, W.-Q., & Liu, L. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10295-x
ASCO 2025 highlights: emerging therapies and biomarkers in pancreatic ductal adenocarcinoma
Windhager, H., & Doleschal, B. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01078-9
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
Groszewska, J., Romaniuk, M., & Małecka-Wojciesko, E. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5040055
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Lin, E. W., Pathak, P., O’Shea, A., Awasthi, B. W., Phillips, I. E., Kocher, J. R., Song, Y., Raabe, M. J., Xu, K. H., Patel, B. K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2052 · Cited by 1
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S.-H., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25123881
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S.-H., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26675240
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S.-H., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25124095
Non-Coding RNA-GATA Axis: Mechanisms and Implications in Cancer Progression and Metastases
Kumar, A., Daimary, U. D., Hegde, M., Abbas, M. A. E., Alqahtani, M. S., Almubarak, H. A., Tergaonkar, V., Sethi, G., & Kunnumakkara, A. B. (2025) · Cancers · doi:10.3390/cancers18010143
Akbar, A., Levya, A., Esnakula, A. K., Hasanov, E., Noonan, A. M., Manne, U., Sahai, V., Meng, L., Tsai, S., Parwani, A. V., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8545050/v1
Chen, L., Chen, J., Wang, Z. P., Jiang, X., Cao, J., Yang, H., Wen, X., & Li, J. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70259
Koyama, K., TAKAHASHI, K., Yusuke, O. N. O., Oyama, K., Tamamura, N., Tanaka, H., Asai, F., Kobayashi, Y., Maeda, C., Ohtaki, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02382-9
梁, 长. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1631112
Semaan, K., Eid, M., Vasseur, D., Gulati, G. S., Lima, C. F. P., Ibrahim, É., Seo, J.-H., Canniff, J., Savignano, H., Jordan, A. C., et al. (2026) · medRxiv · doi:10.64898/2026.04.02.26349987 · Cited by 1
Yu, Y.-N., Jin, S.-Q., Lu, Y.-T., & Han, L.-Z. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i4.117197
Yeo, S. J., Ian Tate Ek Ern, S. I. M., Tay, H. Y., Tai, D., Shi, R., & Chan, J. H. (2026) · Discover Oncology · doi:10.1007/s12672-026-05091-0
MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma
徐慧文, Wang, Q., Cao, R., Qiu, Z., Liu, Y., Hu, J., Zheng, G., & Cheng, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1744566
Extra-lineage tissue programs define the transcription states of human pancreatic cancerPreprint
Ge, S., Tonon, P., Xu, J., Jang, G.-H., Nowlan, F., Min, J., Ng, K., Figueroa, E. F., Zhang, A. X. W., Chan‐Seng‐Yue, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721655 · Cited by 1
Self-citationMolecular Subtypes of Pancreatic Cancer: A Review of the Literature
Wnuk, J. S., Skowron, W., Długaszek, A., Sadurska, J., Pietrzyński, Ł., Kabut, J., & Gisterek, I. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48050502
Shen, S., Qian, X., Shi, Z., Wu, Y., Zhou, Z., Nie, S., Yu, Y., Zhou, S., Liu, K., Zhou, Q., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115950
Lefas, A. Y., Lote, H., & Chau, I. (2026) · Precision Oncology · doi:10.3390/precisoncol1020009
Mandloi, A., Larson, C. R., Tran, T. M., Roy, S., Khaliq, A. M., Fang, Y.-H. D., Baines, J., Laube, R., Patel, M., Risley, C. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728281
Mount, J., Mount, B., Rutenberg, M. S., & Stauffer, J. A. (2026) · Radiation · doi:10.3390/radiation6030022
Oo, H. M., Anekpuritanang, T., Angkathunyakul, N., Degirmenci, U., Pongpaibul, A., Punyawatthananukool, S., Korphaisarn, K., & Sampattavanich, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.28.734525
Yang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
Yaşar, Ş., Yağın, F. H., Alzakari, S. A., Alkhalifa, A. K., Al-Hashem, F. H., & Tabnjh, A. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156989
A Compact, Standalone & Battery-Powered 3D Organoid-on-Chip System with Programmable Flow ControlPreprint
Thakur, R., Murthy, V., Olsen, S., Wolcott, E. A., Budkina, D. S., Anderson, F., Zheng, T., Wright, A. P., Copperman, J., Bertassoni, L. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.02.742326
Limitations of GATA6 and CK5 as surrogate markers for molecular subtyping in pancreatic cancer
Lee, J. J., Aldakkak, M., Doucette, S., Liu, Y., McCabe, I. C., Rashid, N. U., Iuga, A. C., Evans, D. B., Tsai, S., & Yeh, J. J. (2026) · HPB · doi:10.1016/j.hpb.2026.08.001
Kang, S., Parikh, M., Pappas, L., Bi, L., Koenig, J. L., Yeap, B. Y., Carzo, N., Grillo, T. M., Baiev, I., Asupoto, O., et al. (2026) · medRxiv · doi:10.64898/2026.08.06.26359422
Heckelmann, B., Fetzner, D., Lapshyna, O., Hidam, A. K., Bräuer, A., Wandmacher, A. M., Färber, B., Duhn, J., ten Winkel, M., Bolm, L., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01663-z
Continuous tissue fields organize immune composition in pancreatic cancerPreprint
Wang, W., Sarkar, S., Hasselluhn, M. C., Lui-Leung, N., Coka, L. D., Siolas, D., Марченко, Н. В., Escobar‐Hoyos, L. F., Egeblad, M., Sherman, M. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.22.746444
Khan, I., Belhaj, A., Gemini, A., Ibis, K. A., Darsif, N., Rouani, N., Vanlander, A., & Messaoudi, N. (2026) · Cancers · doi:10.3390/cancers18172733
Jung, E., Jeong, H.-C., & Lee, K.-R. (2026) · Organoid · doi:10.51335/organoid.2026.6.e9
The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer
Schaefer, M. L., Tsai, S., & Blair, A. B. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20366-0
Choi, Y., Lee, E. J., Oh, D. H., Kim, H., Woo, S. M., Chun, J. W., & Kong, S. (2026) · Organoid · doi:10.51335/organoid.2026.6.e8
Hemorrhage-Induced Bias of [18F]FDG PET Signal Interpretation in Pancreatic Ductal AdenocarcinomaPreprint
Karampour, R., Steinhelfer, L., Liu, J., Balaji, A., Weidle, S., Steiger, K., Schilling, F., Heid, I., & Braren, R. (2026) · Research Square · doi:10.21203/rs.3.rs-10932499/v1
Yamamoto, N., Dobersch, S., Robertson, T. M., Sim, J. H., Wallace-Povirk, A., Chew, N. W., Orellana, A. E., Aggrey-Fynn, J. E., Boila, L. D., Schutter, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.02.754697
Self-citationSewell, P. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1941793
Ryan, D. H., Ohara, Y., Kruhlak, M. J., Zhang, X., Lin, M., Tai, C., & Alewine, C. (2026) · Cancer Medicine · doi:10.1002/cam4.72322
Fu, B., Tan, Y., Chen, Y., Su, Y., Cao, M., Tan, D., Zhang, M., Chen, X., & Hu, R. (2026) · Cancers · doi:10.3390/cancers18203410
Kim, S., Galam, L., Choi, J., Park, J.-E., Kang, C. M., & Bang, S. (2024) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10821762
Metadata
- Authors
- O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., Lam, B., Krzyzanowski, P. M., Lungu, I. M., Bartlett, J. M. S., Peralta, M., Vyas, F., Khokha, R., Biagi, J., Chadwick, D., Ramotar, S., Hutchinson, S., Dodd, A., Wilson, J. M., Notta, F., Zogopoulos, G., Gallinger, S., Knox, J. J., & Fischer, S. E.
- Affiliations
- 1Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
- Ontario Institute for Cancer Research (CA)
- University Health Network (CA)
- Research Institute of the McGill University Health Centre (CA)
- Kingston General Hospital (CA)
- ORCID
- Grünwald, Barbara T.
- Jang, Gun-Ho
- Grant, Robert C.
- Denroche, Robert E.
- Zhang, Amy
- Wang, Yifan
- Miller, Jessica K.
- Lam, Bernard
- Krzyzanowski, Paul M.
- Lungu, Ilinca M.
- Bartlett, John M.S.
- Peralta, Melanie
- Vyas, Foram
- Khokha, Rama
- Biagi, James
- Ramotar, Stephanie
- Hutchinson, Shawn
- Dodd, Anna
- Wilson, Julie M.
- Notta, Faiyaz
- Zogopoulos, George
- Knox, Jennifer J.
- Fischer, Sandra E.
- Venue
- Clinical Cancer Research
- Published
- 2020-03-10
- Volume
- 26
- Issue
- 18
- Pages
- 4901-4910
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3011562658
- Semantic Scholar
- d72ef3593540c2afcd56ffaaa1ecbdf174cca98b
- Cited by
- 352
- References
- 39
- Citations by year
- 2026: 54 · 2025: 58 · 2024: 58 · 2023: 60 · 2022: 48 · 2021: 56 · 2020: 16
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-06-13)
- Open access
- Licence
- other-oa
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Princess Margaret Cancer Foundation (ALTF 116-2018, DEU 1199182 FLF-P)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- GATA6, pancreatic ductal adenocarcinoma, basal-like subtype, classical subtype, cancer subtyping, chemoresistance, modified FOLFIRINOX, overall survival, prognostic factors, keratin 5, tumor hypoxia, COMPASS trial
- MeSH terms
- Irinotecan, Oxaliplatin, RNA-Seq, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Prospective Studies, Multicenter Studies as Topic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, GATA6 Transcription Factor, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
